First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer

NCT05393440 | Unknown Phase 1

• 1 other identifier: CC-OV01
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.

Conditions

Uterine Cervical Neoplasms

Keywords

Uterine Cervical Neoplasms; Oncolytic viruses; BS-006; Phase I clinical trial; Investigator initiated trial

Outcome Measures

Primary Outcomes (3)

• Maximal tolerable dose

  The dose level at which there is no more than one DLT happens in dose-escalation stage

  2 months after initiation of enrollment

• Rate and grade of adverse events

  The incidence of adverse events and severity graded according to CTCAE 5.0

  From enrollment to 90 days after last treatment of all subjects

• Cope numbers of BS-006

  Detection of BS-006 virus copy numbers in urine, stool, saliva, blood and wiper of injection point and perineum

  1 hours predose and 0.5 hours post-dose for first three doses and 1 hours predose ever after

Secondary Outcomes (4)

• Tumor response rate

  Up to 2 years

• Abscopal effect rate

  Up to 2 years

• Progression free survival rate

  Up to 2 years

• Overall survival rate

  Up to 2 years

Study Arms (2)

Dose-escalation cohort

EXPERIMENTAL

Three subjects will be enrolled in this cohort. First subject will receive first injection in dose level of 1 million CCID50/mL. If tolerated, second injection for this subject will be accelerated to 10 millions CCID50/mL. If tolerated, the third injection will be further accelerated to 100 million CCID50/mL. The maximum volume for per injection time point is 8 mL. Injection will repeat every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. If dose limiting toxicity (DLT) happens in any dose level, the injection dose will be decrease to the last tolerable level.

Biological: BS-006

Dose-expansion cohort

EXPERIMENTAL

Fifteen subjects will be enrolled in this cohort. The maximal tolerable dose (MTD) confirmed in the first stage will be utilized in 15 patients. This stage should not be initiated before the completion of dose escalation of all three subjects in the first stage. Treatment will be repeated every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. Dose interruption, not reduction, is permitted. Treatment will be terminated if toxicity-related treatment interrupt is longer than 28 days. Radiology assessment will be conducted every six weeks.

Biological: BS-006

Interventions

BS-006 BIOLOGICAL

BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.

Also known as: Recombinant oncolytic type II herpes simplex virus

Dose-escalation cohort; Dose-expansion cohort

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Older than 18 years old and younger than 75 years old;
• Zubrod-ECOG-WHO performance status is 0-1;
• Life expectancy is longer than 3 months;
• Pathologically proven malignant tumor originating from cervix uterine. All pathological types are acceptable except for sarcoma of any subtypes;
• Radiological confirmed progression after at least 2 lines prior treatment or intolerable toxicity events occur during the second or later line treatment: 1) Neoadjuvant or adjuvant chemotherapy for no less than 2 cycles should be regarded as a separate treatment line if disease progress within 6 months after treatment finish;2) Regional treatment such as brachytherapy, radiofrequency ablation and artery embolization therapy should not be considered as a treatment line; 3) Treatment shift due to toxicity without radiological progression should not be counted as a separate line;
• At least one measurement lesion according to RECIST 1.1;
• At least one lesion with maximum diameter is larger than 1cm and surgically accessibility;
• Patients must have recovered from prior treatment related toxicity to CTCAE grade 1 or 0;
• Time interval to last systematic treatment or radiation affecting more than 20% bone marrow must be more than 4 weeks;
• Time interval to last major surgery must be more than 4 weeks;
• Abundant organ function: 1) Absolute neutrophil count is more than 1500/mm3 without granulocyte colony stimulating factor in the prior 7 days or long-acting granulocyte colony stimulating factor in the prior 20 days; platelets count is more than 100,000/mm3 without thrombopoietic drugs in the prior 7 days or platelet transfusion in the prior 10 days; hemoglobin is more than 9.0g/dL without red blood cell transfusion in the prior 20 days; 2) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are lower than 2.5-fold upper limit of normal (ULN); serum bilirubin is lower than 1.5-fold ULN; serum albumin is more than 3g/dL; 3) Serum creatinine is lower than 1.5-fold ULN; 4) Prothrombin time and activated partial thromboplastin time is lower than 1.3-fold ULN;
• Patients must have fully recovered from suspected or diagnosed genital herpes beyond 3 months;
• Patients or their legally authorized representative must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirement;
• Women of childbearing potential must agree to use highly effective contraceptive methods in while on study drug and for at least 3 months after the last injection of BS-006. The pregnancy test within 7 days prior to the first injection must be negative.

You may not qualify if:

• Cervical sarcoma of any subtype or prior history of other malignancy within 5 years;
• Central nerve system metastasis;
• Severe comorbidities of any organs, including but not limit to myocardial infarction within 6 months, unstable angina pectoris, congestive heart failure, grade 3 or higher hypertension per CTCAE, cardiac arrhythmias, uncontrolled diabetes, fever of unknown reason, active digest ulcer and chronic obstructive pulmonary disease;
• History of central nervous system infectious or demyelinating disease;
• Severe infectious disease requiring constant antibiotic treatment;
• Systematic glucocorticoids use within 2 weeks or glucocorticoids need for a long term;
• Active infection of hepatitis B or C, HIV, cytomegalovirus, syphilis or other virus requiring treatment;
• Immune disorder disease;
• Antiviral treatment of any kinds;
• Prior participant in experimental viral therapy;
• Allergy to herpes simplex virus vaccine;
• Participation in another research study within 4 weeks;
• Poor compliance or incapacitated patients due to mental illness or other reasons;
• Pregnancy or lactation.

Sponsors & Collaborators

• Zhongnan Hospital: lead
• Binhui Biopharmaceutical Co., Ltd.: collaborator

Study Sites (1)

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

RECRUITING

Related Publications (4)

• Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020 Oct 2;16(10):2389-2402. doi: 10.1080/21645515.2020.1723363. Epub 2020 Feb 20.

  PMID: 32078405 BACKGROUND

• Kohlhapp FJ, Kaufman HL. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clin Cancer Res. 2016 Mar 1;22(5):1048-54. doi: 10.1158/1078-0432.CCR-15-2667. Epub 2015 Dec 30.

  PMID: 26719429 BACKGROUND

• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.

  PMID: 26014293 BACKGROUND

• Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer. 2018 Dec 4;6(1):140. doi: 10.1186/s40425-018-0458-z.

  PMID: 30514385 BACKGROUND

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Officials

• Hui Qiu, Ph. D.

  Wuhan University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Shaoxing Sun, M. D.

CONTACT

+08613871286154; sunshaoxing@whu.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician and Director of Department of Radiation and Clinical Oncology (Gynaecological Oncology

Study Record Dates

• First Submitted: May 19, 2022
• First Posted: May 26, 2022
• Study Start: September 16, 2022
• Primary Completion: December 31, 2023
• Study Completion: July 1, 2024
• Last Updated: April 7, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)